1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Cohance Lifesciences Limited

Cohance Lifesciences Limited

COHANCE.NS
Cohance Lifesciences LimitedIN flagNational Stock Exchange of India
452.95
INR
-1.55
- -
173.28BMarket Cap

Total Valuation

Cohance Lifesciences Limited carries a market capitalization of 173.28B, placing it among publicly traded companies globally. Its enterprise value stands at 117.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap173.28B
Enterprise Value117.19B

Share Statistics

Cohance Lifesciences Limited currently has 382.57M shares outstanding.

Shares Outstanding382.57M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Cohance Lifesciences Limited trades at a trailing price-to-earnings ratio of 64.32. The price-to-sales ratio is 5.08, and the price-to-book ratio stands at 301.19.

PE Ratio64.32
PS Ratio5.08
PB Ratio301.19
P/TBV Ratio4.35
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Cohance Lifesciences Limited trades at an EV/EBITDA multiple of 48.90 and an EV/FCF ratio of 434.00. The EV/Sales ratio of 5.17 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 48.90 provides insight into valuation relative to core operating earnings.

EV / Sales5.17
EV / EBITDA48.90
EV / EBIT48.90
EV / FCF434.00

Financial Position

Cohance Lifesciences Limited maintains a current ratio of 2.83, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.93, indicating elevated leverage, while an interest coverage ratio of 6.44 demonstrates adequate ability to service its debt obligations.

Current Ratio2.83
Quick Ratio0.51
Debt / Equity9.93
Debt / EBITDA1.67
Interest Coverage6.44

Financial Efficiency

Cohance Lifesciences Limited posts a return on equity of 24.75 and a return on invested capital of 5.29.

Return on Equity (ROE)24.75
Return on Assets (ROA)4.09
Return on Invested Capital (ROIC)5.29
Return on Capital Employed (ROCE)19.66
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.82

Taxes

Over the trailing twelve months, Cohance Lifesciences Limited has paid 569.20M in income taxes, reflecting an effective tax rate of 27.49.

Income Tax569.20M
Effective Tax Rate27.49

Stock Price Statistics

Cohance Lifesciences Limited's stock has declined approximately -55.56918% over the past 52 weeks. The 50-day moving average sits at 443.75, while the 200-day moving average is 487.14.

Beta (5Y)N/A
52-Week Price Change-55.56918%
50-Day Moving Average443.75
200-Day Moving Average487.14
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Cohance Lifesciences Limited generated 22.69B in revenue and converted that into 1.79B in net income, yielding earnings per share of 3.89. EBITDA reached 2.40B, while operating income came in at 2.40B.

Revenue22.69B
Gross Profit16.06B
Operating Income2.40B
Pretax Income2.07B
Net Income1.79B
EBITDA2.40B
EBIT2.40B
Earnings Per Share (EPS)3.89

Balance Sheet

Cohance Lifesciences Limited holds 3.28B in cash and equivalents against 4.00B in total debt, resulting in a net debt position of 1.21B. Total book value stands at 382.60M, with working capital of 11.82B providing operational flexibility.

Cash & Cash Equivalents3.28B
Total Debt4.00B
Net Debt1.21B
Equity (Book Value)382.60M
Book Value Per Share1.00
Working Capital11.82B

Margins

Cohance Lifesciences Limited operates with a gross margin of 70.79, reflecting its pricing power and cost economics. The operating margin of 10.56 and net profit margin of 7.90 provide insight into operational efficiency.

Gross Margin70.79
Operating Margin10.56
Pretax Margin9.13
Profit Margin7.90
EBITDA Margin10.56

Stock Splits

Cohance Lifesciences Limited's most recent stock split took place on September 25, 2020 with a 1:2 split ratio.

Last Split Date9/25/2020
Split Ratio1:2

Scores

Cohance Lifesciences Limited posts an Altman Z-Score of 5.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.11